The Microbiome’s Influence on Immunotherapy
By: Gene Yang ‘19 When it was discovered that cancer cells with the protein PD-L1 avoid detection by the immune system, clinical trials involving PD-L1-targeted drugs emerged. These drugs, part of a class known as immune checkpoint inhibitors, block the interaction between the cancer cells’ PD-L1 protein and the immune system’s T cells, which then allows the immune system to detect and attack the tumor. … Continue reading The Microbiome’s Influence on Immunotherapy

